Borhane Slama

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

Mehdi Khellaf, Anaïs Charles‐Nelson, Olivier Fain et al. · Blood · 2014 · 167 citations · Full text

Medicine, Hematology, Immunology +9

Mutation analysis of <i>ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,</i> and <i>TET2</i> in myeloproliferative neoplasms

Mandy Brecqueville, Jérôme Rey, François Bertucci et al. · Genes Chromosomes and Cancer · 2012 · 153 citations

Medicine, Genetics, Molecular Genetics +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

Mehdi Khellaf, Marc Michel, Philippe Quittet et al. · Blood · 2011 · 111 citations · Full text

Medicine, Hematology, Immunology +7